Search Results

Biotech Bay

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Biomea Fusion, Inc., announced that the Company has received notice from the U.S. Food and Drug Administration that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes, respectively.

June 6, 2024

·

6 min read

Deals

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion, Inc. today announced that on June 1, 2024, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares.

June 3, 2024

·

1 min read

Press Releases

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

October 30, 2024

·

10 min read

Press Releases

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

October 22, 2024

·

4 min read

Biotech Bay

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 01, 2024

Biomea Fusion, Inc. announced that on May 1, 2024, the compensation committee of Biomea’s board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of the Company’s common stock.

May 1, 2024

·

1 min read

Business

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported first quarter 2024 financial results and corporate highlights.

May 2, 2024

·

11 min read

Business

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Biomea Fusion, Inc. reported fourth quarter and full year 2023 financial results and corporate highlights.

April 1, 2024

·

14 min read

Biotech Bay

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. today announced the completion of enrollment of the first three dose expansion arms of COVALENT-111, with a total of over 260 type 2 diabetes patients enrolled.

May 30, 2024

·

5 min read

Biotech Bay

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024

Biomea Fusion, Inc. announced that on April 1, 2024, the compensation committee of Biomea’s board of directors granted two new employees non-qualified stock options to purchase an aggregate of 6,500 shares of the Company’s common stock.

April 1, 2024

·

1 min read

Pictured: The front entrance to the FDA headquarters/iStock, Grandbrothers

Drug Development

Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate

Biomea Fusion’s early-stage investigational diabetes treatment BMF-291 has been slapped with a full FDA clinical hold on its Phase I/II trials due to concerns over liver toxicity.

June 7, 2024

·

1 min read

·

Tyler Patchen